Oculis (NASDAQ:OCS) Announces Earnings Results, Beats Expectations By $0.11 EPS

Oculis (NASDAQ:OCS) announced its earnings results on Tuesday. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.11, FiscalAI reports. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.26 million. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%.

Oculis Price Performance

Shares of NASDAQ OCS traded down $0.08 during trading on Tuesday, hitting $7.63. The company had a trading volume of 541,788 shares, compared to its average volume of 419,890. The firm has a market capitalization of $442.42 million, a price-to-earnings ratio of -4.39 and a beta of 0.67. The stock has a fifty day simple moving average of $9.64 and a two-hundred day simple moving average of $18.70. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01. Oculis has a fifty-two week low of $7.11 and a fifty-two week high of $34.47.

Wall Street Analysts Forecast Growth

OCS has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Thursday, October 15th. Wall Street Zen raised Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. JPMorgan Chase & Co. dropped their price target on Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Finally, HC Wainwright restated a “buy” rating and set a $39.00 price objective on shares of Oculis in a report on Wednesday, October 21st. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $39.44.

About Oculis

Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.

Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.